Alpha Cognition Secures U.S. Patent for Alzheimer’s Drug

TipRanks Canadian Auto-Generated Newsdesk

Story Highlights

Alpha Cognition received a Notice of Allowance from the USPTO.
The patent strengthens protection for ZUNVEYL until 2044 in the U.S.
Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.

Alpha Cognition Secures U.S. Patent for Alzheimer’s Drug

Alpha Cognition Inc (TSE:ACOG) has released an update.

Claim 55% Off TipRanks

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Alpha Cognition Inc. has received a Notice of Allowance from the USPTO for its patented Alzheimer’s drug, ZUNVEYL, which strengthens its intellectual property protection in the U.S. until 2044. This milestone supports the company’s mission to develop innovative therapies for neurodegenerative diseases.

For further insights into TSE:ACOG stock, check out TipRanks’ Stock Analysis page.